Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Working Capital Changes (2017 - 2025)

Puma Biotechnology's Other Working Capital Changes history spans 9 years, with the latest figure at $26000.0 for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 108.02% year-over-year to $26000.0; the TTM value through Dec 2025 reached -$702000.0, up 59.72%, while the annual FY2025 figure was $1.2 million, 85.82% up from the prior year.
  • Other Working Capital Changes reached $26000.0 in Q4 2025 per PBYI's latest filing, down from $850176.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $850176.0 in Q3 2025 to a low of -$870000.0 in Q1 2023.
  • Average Other Working Capital Changes over 5 years is $177099.8, with a median of $104769.0 recorded in 2023.
  • Peak YoY movement for Other Working Capital Changes: plummeted 388.89% in 2021, then soared 19925.0% in 2022.
  • A 5-year view of Other Working Capital Changes shows it stood at -$4000.0 in 2021, then skyrocketed by 19925.0% to $793000.0 in 2022, then crashed by 117.4% to -$138000.0 in 2023, then crashed by 134.78% to -$324000.0 in 2024, then soared by 108.02% to $26000.0 in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Other Working Capital Changes are $26000.0 (Q4 2025), $850176.0 (Q3 2025), and $218246.0 (Q2 2025).